- Home
- OWL vs MRNA Comparison
OWL vs MRNA Comparison
Compare OWL & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OWL
- MRNA
- Stock Information
- Founded
- OWL 2020
- MRNA 2010
- Country
- OWL United States
- MRNA United States
- Employees
- OWL N/A
- MRNA N/A
- Industry
- OWL Investment Managers
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OWL Finance
- MRNA Health Care
- Exchange
- OWL Nasdaq
- MRNA Nasdaq
- Market Cap
- OWL 10.6B
- MRNA 9.8B
- IPO Year
- OWL N/A
- MRNA 2018
- Fundamental
- Price
- OWL $16.56
- MRNA $24.70
- Analyst Decision
- OWL Buy
- MRNA Hold
- Analyst Count
- OWL 15
- MRNA 15
- Target Price
- OWL $23.07
- MRNA $37.15
- AVG Volume (30 Days)
- OWL 13.7M
- MRNA 8.9M
- Earning Date
- OWL 10-30-2025
- MRNA 11-06-2025
- Dividend Yield
- OWL 5.45%
- MRNA N/A
- EPS Growth
- OWL 20.13
- MRNA N/A
- EPS
- OWL 0.11
- MRNA N/A
- Revenue
- OWL $2,618,831,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- OWL $17.23
- MRNA N/A
- Revenue Next Year
- OWL $21.81
- MRNA $11.12
- P/E Ratio
- OWL $144.78
- MRNA N/A
- Revenue Growth
- OWL 31.81
- MRNA N/A
- 52 Week Low
- OWL $14.55
- MRNA $23.15
- 52 Week High
- OWL $26.73
- MRNA $57.69
- Technical
- Relative Strength Index (RSI)
- OWL 46.36
- MRNA 43.66
- Support Level
- OWL $16.29
- MRNA $25.57
- Resistance Level
- OWL $17.30
- MRNA $27.37
- Average True Range (ATR)
- OWL 0.63
- MRNA 1.18
- MACD
- OWL 0.10
- MRNA -0.22
- Stochastic Oscillator
- OWL 59.27
- MRNA 7.25
About OWL Blue Owl Capital Inc.
Blue Owl Capital Inc is an alternative asset management firm. The company deploys private capital across Credit, GP Strategic Capital, and Real Estate platforms on behalf of institutional and private wealth clients. The company conducts its operations through Blue Owl Capital Holdings LP (Blue Owl Holdings) and Blue Owl Capital Carry LP (Blue Owl Carry). Its investor base includes a diversified mix of institutional investors, including public and private pension funds, endowments, foundations, family offices, private banks, high-net-worth individuals, asset managers, and insurance companies. The company generates substantially all of its revenues in the United States.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.